buntanetap/posiphen + Placebo
Phase 3RecruitingInterest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Early Alzheimers Disease
Conditions
Early Alzheimers Disease
Trial Timeline
Feb 4, 2025 → Jun 1, 2028
NCT ID
NCT06709014About buntanetap/posiphen + Placebo
buntanetap/posiphen + Placebo is a phase 3 stage product being developed by Annovis Bio for Early Alzheimers Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06709014. Target conditions include Early Alzheimers Disease.
What happened to similar drugs?
2 of 20 similar drugs in Early Alzheimers Disease were approved
Approved (2) Terminated (2) Active (17)
❌PERT-IJS plus trastuzumab, carboplatin and docetaxel + Perjeta plus trastuzumab, carboplatin and docetaxelBioconPhase 3
🔄SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab InjectionJiangsu Hengrui MedicinePhase 3
🔄SHR7280；Ganirelix Acetate Injection simulant + SHR7280 simulant； Ganirelix Acetate InjectionJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
17
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06709014 | Phase 3 | Recruiting |
| NCT05686044 | Phase 2/3 | Completed |
| NCT05357989 | Phase 3 | Completed |
Competing Products
20 competing products in Early Alzheimers Disease